Penicillamine Neurotoxicity: An Hypothesis by Walshe, J. M.
International Scholarly Research Network
ISRN Neurology
Volume 2011, Article ID 464572, 4 pages
doi:10.5402/2011/464572
Research Article
Penicillamine Neurotoxicity: An Hypothesis
J. M. Walshe
Department of Medicine, Medical School, University of Cambridge, Cambridge CB2 2QQ, UK
Correspondence should be addressed to J. M. Walshe, penicillamine@waitrose.com
Received 16 March 2011; Accepted 17 May 2011
Academic Editors: C.-M. Chen and A. Quattrini
Copyright © 2011 J. M. Walshe. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Penicillamine, dimethyl cysteine, thiovaline, remains the drug of choice for the treatment of patience with Wilson disease. It is also
of value in the treatment of cysteinuria and rheumatoid arthritis, it has also been suggested that it has value in the management
of other rare diseases. It also has multiple toxicities. The majority of these can be explained as chemical toxicity, for instance its
weak antipyridoxine action and its ability to interfere with lysyloxidea resulting in skin lesions. More important are its ability to
induce immune reactions such as SLE, immune complex nephritis, the Ehlers Danlos syndrome and Goodpasture’s syndrome.
However the sudden increase in neurological signs which may occur in a small number of patients remains unexplained. The
theory is proposed that this is due to lethal synthesis. In susceptible patients the–SH radical is liberated from penicillamine and
will inhibit–SH dependent enzymes in the Krebs cycle leading to death in neurones. Other toxic metabolites may also be produced
such as methyl mercaptan and ethyl mercaptan either of which could produce a similar metabolic block.
After more than 50 years of experience penicillamine remains
the most eﬀective treatment for patients with Wilson disease
for which there is ample evidence [1, 2]. However it also
has a wide variety of toxicities, most of these can be
explained in terms of chemical or immunological reactions.
But one, the great increase in the neurological deficit remains
unexplained. The present theories are unsatisfactory and this
paper proposes a new hypothesis for the neurotoxicity of
penicillamine which, if correct, may lead to the introduction
of a predictive test which will be of great value in deciding
whether or not this drug can be used as an initial therapy.
In 1948, when he established the role of copper in the
pathogenesis of Wilson disease, Cumings [3] put possible
therapy on a sound scientific basis by suggesting that
the chelating agent BAL, British Antilewisite, might be
beneficial in the management of this disease by removing
the excess copper. This hypothesis was later supported by
his own observations [4] and those of Denny Brown and
Porter in Boston [5]. Later Denny Brown appeared to
have abandoned the copper theory in favour of Uzman’s
hypothesis that the disease was due to an abnormality of
peptide metabolism and that copper was merely deposited
as a secondary phenomenon in dying neurones [6–8]. How
Denny Brown was able to continue to propagate the use
of BAL as an eﬀective therapy in view of his theories
on pathogenesis remains unclear [9]. However the peptide
theory was finally disproved by Asatoor Milne and Walshe
[10] when they showed that there were no abnormal
peptides in the urine of Wilson disease patients and that the
abnormal aminoaciduria could, in most cases, be corrected
by treatment with penicillamine.
When, in 1956, I proposed that penicillamine might be
of use as a chelating agent for copper removal [11] virtually
nothing was known of its potential toxicity except that the
L-isomer, when fed to ethanolamine deficient rats, caused
loss of weight [12]. As the isomer liberated from penicillin is
the the D isomer this did not seem relevant. I speculated on
its potential toxicity and pointed out that as this aminoacid,
in the D form, was present in the urines of all patients
treated with penicillin it was therefore unlikely to have any
immediate toxic eﬀects and supported this by safely taking a
gram myself. However the possibility of long-term toxicity
had to be considered and I suggested “dimethyl cysteine
(penicillamine) might enter into the same metabolic pathways
as cysteine and thereby cause a block. Occurring in the liver a
metabolic block might lead to a conditioned cysteine deficiency
and hepatic necrosis., in the skin it might cause alopecia as does
selenium cystine. These points can be resolved only by long term
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Figure 1: Penicillamine has many suggested beneficial actions as well as many toxicities, treasure trove or Pandora’s box?
study”. Although a small number of patients have complained
of excessive hair loss there have been no reports of total
alopecia and hepatic necrosis also has not been reported.
In practice, with increasing time of dosage and increasing
number of patients treated, a wide spectrum of toxicities have
been reported.
However, before any serious side eﬀects were recorded
came the report in 1963 and that penicillamine formed a
mixed disulphide with cysteine and that this could be used
for the treatment of another, unrelated metabolic disease,
cystinuria [13] and Hartley and Walshe [14] were able to
show that half the penicillamine excreted in urine was in
this form. The first serious side eﬀect to be reported was the
nephrotic syndrome and this led directly to the development
of trientine as an alternative orally active chelating agent
[15]. As penicillamine toxicity became more of a problem
the subject was dealt with in some detail in four symposia,
1968 [16], 1974, [17], 1977 [18], and 1981 [19], held on
this drug. These can be best summarised in a diagram of
1985, (Figure 1). In the 1981 symposium [20] I pointed out
that “Penicillamine toxicity can be resolved into chemically
and immunologically mediated reactions. Chemical toxicity is
dose dependent and, if the drug is withdrawn in time, readily
reversible.” These reactions are also explicable in terms of
the drugs known chemical reactions. For instance the skin
lesions, cutis laxa, elastosis perforans, and epidermolysis can
be explained in terms of the action of penicillamine on
the copper-dependent enzyme lysyl oxidase which mediates
collagen cross-linkage [21]. Similarly the ability of this drug
to cause pyridoxine deficiency results from its ability to
form a thiazolidine with the vitamin. Although, in fact, D-
penicillamine has only a very weak action compared with
that of the L isomer [22]. Muchmore serious are the immune
reactions, such as SLE, the nephrotic syndrome, Goodpasture
syndrome, and Ehlers Danlos syndrome and these all require
immediate drug withdrawal.
A few toxicities remain unexplained, for example, the
very rare mammary gigantism and the immediate and rapid
increase in any or all of the neurological signs already present,
whether they be dystonic, parkinsonian, or pseudosclerotic,
once treatment has been started. The latter is serious andmay
leave the patient severely disabled or even prove fatal if treat-
ment is not stopped immediately. Walshe and Yealland [23]
found this in 11 of 137 patients with predominantly neu-
rological signs. It has been suggested that this complication
is due to the sudden release of ionic copper but this would
seem unlikely as the copper so released is penicillamine
bound and should be nontoxic. One possible mechanism has
been suggested by Miki [24] “However copper-penicillamine
chelates are eﬀective in catalyzing the oxidation of ghost
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membranes, which may be due to favourable alterations in the
redox potential of copper. This acceleration of penicillamine
may explain the initial aggravation of neurological symptoms
often observed with its use.” Another possible aggravating
factor is the low level of urate found in the plasma following
the renal leek of this metabolite [25] as this has antioxidant
properties [26]. In support of this is the observation that
patients with Parkinson’s disease have a slower progression of
their disease if the have higher serum and cerebrospinal fluid
urate levels [27]. I have suggested an alternative explanation
that in these patient there is a particularly unfavourable
mutation, or combination of mutations. Since most patients
are compound heterozygotes and as there are approximately
300 mutations on the aﬀected gene, a P-type ATPase, it
becomes diﬃcult or almost impossible to prove, or disprove
this hypothesis.
In view of the importance of this aspect treatment it
would be advantageous to find a predictive test which could
be used before embarking on any particular line of treatment.
But before this can be achieved it is necessary to understand
the underlying pathogenesis. I propose the following theory,
this as example of what Rudolph Peters called lethal synthesis
[28], that is a nontoxic compound, is changed, by enzyme
action in the body, into a toxic one. Suppose that patients
who react by a sudden neurological deterioration on starting
treatment with penicillamine convert or break down the
molecule into a powerful enzyme inhibitor. Normally peni-
cillamine is either excreted unchanged or as the disulphide
or as the mixed penicillamine-cysteine disulphide. Using
radiolabelled penicillamine I found no evidence of other
breakdown products in either the patient studied or in a
normal control [29]. However if the SH group is removed
from the molecule a free –SH radical or H2S, both highly
toxic [30], might be released into the circulation and could
prove powerful inhibitors of –SH dependent enzymes in
the Krebs cycle, as also would other possible breakdown
products, methyl mercaptan (CH3SH), and ethyl mercaptan
(CH3CH3SH). Sudden inhibition of energy production
by glucose oxidation would certainly prove disastrous to
the CNS as neurons, especially those already damaged by
copper, are heavily dependent on energy production from
glucose. The removal of the SH alone would leave valine, an
alternative name for penicillamine is thiovaline, a normally
occurring amino acid, as an end product of this reaction.
This leaves a possible test for this reaction The molecular
weight of penicillamine is 149, that of valine 117. It follows
that if a test dose of 1 gm of penicillamine be given to
a patient and if all the SH were to be rapidly removed
from the molecule this would leave 785mg of valine in the
circulation. Thus if an increase in plasma or urine valine
levels was to be detected, this might provide a valuable
test for identifying those patients particularly vulnerable to
this form of penicillamine toxicity. An alternative approach
would be to look for the appearance of the SH compounds,
hypothesised above, in plasma. Another possible reaction has
also been suggested [31] that “If RS-radicals of penicillamine
react with protein disulphide bridges with resultant formation
of trisulphides, irreversible damage might be done. This may
occur by a simple sulphur exchange mechanism RS + R′SSR –
R + R′SSR′ or by a sequence of reactions trisulphide formations
in proteins will exchange with the tertiary structure and in
many cases would be harmful. Thus although penicillamine
scavenges free radicals eﬃciently and repairs alkyl radicals
rapidly, the thiyl radicals formed may not be harmless”. If
lethal synthesis explains this rare aspect of penicillamine
neurotoxicity it does not necessarily explain the toxic
reactions of other treatments, though it might be applicable
to trientine it cannot be relevant to deterioration noted with
zinc or tetrathiomolybdate where other mechanisms must be
involved.
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